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Background: Selecting patients according to key genetic character-
istics may help to tailor chemotherapy and optimize the treatment in
non-small cell lung cancer (NSCLC). Genetic variations in drug me-
tabolism may affect the clinical response, toxicity, and prognosis of
NSCLC patients treated with cisplatin/gemcitabine-based therapy.
Patients and Methods:We evaluated seven single-nucleotide poly-
morphisms of six genes CDA Lys27Gln (A/C); CDA C435T;
ERCC1 C118T; XRCC3 Thr241Met (C/T); XPD Lys751Gln (A/C);
P53 Arg72Pro (G/C), and RRM1 C524T in 192 chemotherapy-naive
patients with advanced NSCLC treated with cisplatin/gemcitabine-
based regimen by TaqMan probe-based assays with 7300 Real-Time
PCR System, using genomic DNA extracted from blood samples.
Results: The CDA 435 T/T genotype was significantly associated
with better response (p  0.03). The CDA 435 C/T genotype was
associated with a significantly increased risk of nonhematological
toxicity of grade 3 (p  0.02) after adjusting for performance
status, age, and type of treatment regimen. In the multivariate Cox
model, the XPD 751 C/C genotype was a significant prognostic
factor of longer progression-free survival (p  0.006).
Conclusion: Our data suggest polymorphic variations of drug met-
abolic gene were associated with response and toxicity of cisplatin/
gemcitabine-based therapy and progression-free survival of patients
with advanced NSCLC.
Key words: Polymorphisms, Response to chemotherapy, Toxicity,
Survival, Advanced NSCLC.
(J Thorac Oncol. 2011;6: 2018–2026)
The combination of two cytotoxic drugs, a platinum andnonplatinum agent, is the standard of care for first-line
treatment of patients with advanced non-small cell lung
cancer (NSCLC) and good performance status (PS, 0 to 1).1
In an attempt to improve activity and efficacy of current
regimens, a pharmacogenetic approach has been advocated.
Pharmacogenetics may reduce the variation in how individual
patients respond to medicines by tailoring therapies to their
genetic profile.2 Cisplatin activity is mediated through the
formation of cisplatin-DNA adducts. Removal of these ad-
ducts, which leads to chemoresistance, is mainly carried out
by the nucleotide excision repair system, which consists of at
least 30 identified genes, including excision repair cross-
complementing group 1 (ERCC1) and xeroderma pigmento-
sum group D (XPD).3 Single-nucleotide polymorphisms
(SNP) in any of these genes may modulate repair capacity
and contribute to individual variations in chemotherapy re-
sponse. In vitro analysis showed that the C/T SNP at codon
118 of the ERCC1 gene affected mRNA and protein levels,
leading to differential cisplatin sensitivity.4 Furthermore,
clinical data suggested a possible correlation of this SNP with
clinical outcome and tumor response to platinum-based che-
motherapy in advanced colorectal cancer and a significant
correlation with survival in advanced NSCLC.5–8 Two non-
synonymous polymorphisms occurring in XPD, the aspartic
acid 312 asparagine (Asp312Asn) and the lysine 751 glu-
tamine (Lys751Gln) have been associated with a differential
DNA repair efficiency.9,10 Some studies in lung cancer pa-
tients showed no significant association between clinical
outcome and the C/C genotype in codon 118 of ERCC111,12
and with polymorphisms at codons 312 and 751 in
XPD.7,8,12,13
Other gene, the x-ray repair cross-complementing
group 3 (XRCC3), belongs to the homologous recombination
pathway, which actively repairs the DNA double-strand
breaks induced by chemotherapy. The polymorphism in
codon 241 (Thr to Met) of XRCC3 has been associated with
the level of bulky DNA adducts in leukocytes of healthy
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subjects,14 with chemosensitivity to therapy15 and with a
higher risk of developing lung cancer.16
Moreover, TP53 plays a central role in DNA synthesis,
repair, and apoptosis; a polymorphism at codon 72 (Arg to
Pro)17 has been associated with survival in head and neck
cancer patients receiving cisplatin-based chemoradiotherapy,
with patients harboring the Arg allele having longer survival
than those with the Pro allele.18 Human NSCLC cell lines
with TP53 mutations at codons 273 and 282 were resistant to
cisplatin/gemcitabine in the presence of the 72 Arg allele but
not in that of the 72 Pro allele.19
Ribonucleotide reductase, a key enzyme for DNA syn-
thesis, is involved in DNA repair and in gemcitabine metab-
olism. A C to A substitution in the 59 noncoding region of the
subunit M1 (RRM1), located 37 base-pairs upstream of the
start codon and has been linked to RRM1 expression levels,
with high levels in patients with the variant allele.20
The metabolic inactivation of gemcitabine is catalyzed
primarily by cytidine deaminase (CDA), but few studies have
evaluated the pharmacogenetics of this enzyme reporting
controversial results. In particular, Gilbert et al21 have ob-
served a significant decrease in deamination activity of gem-
citabine in a CDA variant characterized by the nonsynony-
mous polymorphism of lysine 27 glutamine (Lys27Gln),
resulting from an A to C substitution in exon 79, whereas
Kirch et al22 reported opposite results with cytarabine as the
substrate. Moreover, sensitivity to cytarabine was not
changed by introducing polymorphic 27Gln CDA into yeast
CDA-null mutants.23 Other in vitro studies did not show any
relationship between CDA activity and sensitivity to gemcit-
abine or cytarabine24,25; only cells with transfected CDA and
thus with a very high CDA activity were less sensitive to
gemcitabine.26 Hence, CDA might be a key enzyme in the
mechanism of inactivation of gemcitabine, but the role of its
polymorphism is still controversial. Nevertheless, few clini-
cal studies have shown a positive association between CDA
SNP and drug toxicity.27,28 Taken together, these observa-
tions suggest that several SNPs may affect key genes in-
volved in cisplatin and gemcitabine mechanism of action and
may influence clinical outcome. Therefore, we retrospec-
tively evaluated the correlations of ERCC1 C118T; P53
Arg72Pro; XRCC3 Thr241Met; XPD Lys751Gln; RRM1
C524T; CDA Lys27Gln; and CDA C435T polymorphisms on
germ line DNA obtained from NSCLC patients receiving
cisplatin/gemcitabine-based therapy with drug response, tox-
icity, and survival.
PATIENTS AND METHODS
Patient Selection Criteria
Chemotherapy-naive patients with histologically or cy-
tologically proven NSCLC and measurable clinical stage IIIB
or stage IV disease were eligible if they also met the follow-
ing criteria: an Eastern Cooperative Oncology Group perfor-
mance status2, age18 years, life expectancy3 months,
adequate bone marrow reserve (leukocyte count 4.0 
109/L and platelet count 100  109/L), adequate liver
(bilirubin level 1.5 mg/dL and alanine aminotransferase/
aspartate aminotransferase 3 times the upper limit of
normal), and renal function (creatinine level 1.5 mg/dL).
The main exclusion criteria were active infections, concom-
itant malignancy, or a second primary malignancy, recent
myocardial infarction, unstable angina, symptomatic brain
metastases, or hypercalcemia. The primary endpoints were
response to chemotherapy and toxicities according to SNPs
genotyping status and secondary endpoints were progression-
free survival (PFS) and overall survival (OS).
Eligible types of treatment were as follows: cisplatin/
gemcitabine regimens (75 mg/m2 of cisplatin infused over 60
minutes given on day 1 plus 1 g/m2 of gemcitabine admin-
istered intravenously over 30 minutes on day 1 and day 8 and
every 3 weeks), cisplatin/taxol regimens (75 mg/m2 of cis-
platin on day 1 and 175 mg/m2 of taxol on day 1 and every
3 weeks), cisplatin/vinorelbine regimens (75 mg/m2 of cis-
platin on day 1, plus 25 mg/m2 of vinorelbine on day 1 and
day 8 and every 3 weeks), or gemcitabine alone. All chemo-
therapeutic drugs were administered intravenously, and pa-
tients were treated for four to six cycles, with a median of
four cycles. No patient had received thoracic radiotherapy.
Treatment was discontinued in case of disease progression,
major toxicities, or according to the patient’s or physician’s
decision. Assessment of tumor response was carried out by
computed tomography scan every three cycles. Responses
were assessed using Response Evaluation Criteria in Solid
Tumors.29 The best overall response for each patient was
reported, and all responses were reviewed by an independent
radiologist and had to be confirmed 28 days or more after the
initial documentation of response. Toxicity was expressed as
the number of patients who experienced a certain grade of an
adverse event at least once during the study. Hematologic and
nonhematologic toxicities were recorded at day 1 and 8 of
every treatment course. The worst toxicity grade for each
patient in all chemotherapy cycles was reported. Toxicities
were assessed using National Cancer Institute common ter-
minology criteria (version 3.0). The analysis of the samples
was done in a blinded fashion relative to the clinical outcome.
The study was approved by an Ethical Review Committee at
the hospital and all patients gave their signed informed
consent to SNPs genotyping analyses.
DNA Extraction and SNP Genotyping
Genomic DNA was extracted from whole blood sam-
ples (5 ml) using the QIAamp DNA extraction kit on Bioro-
bot EZ1 instrument (Qiagen, Milan, Italy) according to the
manufacturer’s instructions. In this exploratory investigation,
we evaluated seven SNPs of the ERCC1, P53, XRCC3, XPD,
RRM1, CDA genes according to the following criteria: (a) the
minor allele frequency of the SNP is 10% among Cauca-
sian; (b) coding SNPs including nonsynonymous and synon-
ymous SNP; and (c) SNPs that have been associated with
cancer risk or clinical outcome in previous investigations.
The genes, nucleotide substitutions, and reference SNP iden-
tification numbers of the seven SNPs evaluated in this study
are summarized in Table 1.
SNPs were studied with Taqman probe-based assays
using primers and probe sequence as previously published by
other authors.12,30 The polymerase chain reactions (PCRs)
were done using 20 ng of genomic DNA diluted in 11.875 L
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DNase-RNase-free water, 12.5 L of TaqMan Universal
PCR Master Mix with AmpliTaq Gold, and 0.625 L of the
assay mix (forward and reverse specific primers and the
specific probes), in a total volume of 25 L. Amplification
was done under the following conditions:50°C for 2 minutes,
95°C for 10 minutes followed by 40 cycles of 92°C for 15
seconds, and 60°C for 1 minute. Fluorescence in each sample
well was measured before and after PCR using ABI Prism
7300 Sequence Detection System. Data were analyzed using
the Allelic Discrimination Program (Applied Biosystems,
Foster City, CA). For each polymorphism, a minimum of 20
randomly selected DNA samples were genotyped at least
twice to confirm the results.
Statistical Analysis
All patients meeting the criteria for eligibility were
considered for analysis. Association between genotypes and
response was evaluated using a logistic regression model.
The results, expressed as odds ratios with 95% confidence
intervals (95% CIs), are reported. The same approach was
used to investigate the association between genotypes and
toxicity. PFS was defined as the time from the onset of
treatment to the first appearance of progressive disease or
death for any cause; patients known to be alive and free of
progressive disease at the time of analysis were censored at
their last available follow-up assessment. OS was defined as
the time from the beginning of treatment to the date of death
from any cause or the date of the last follow-up. Survival
curves were estimated using the Kaplan-Meier method. The
Cox proportional hazards model was used for univariate
analysis that tests demographic characteristics (gender, age,
and smoking status) and clinical features (performance status,
histology, and stage) for their association with PFS and OS.
Variables with a p value 0.1 in the univariate model were
considered for the multivariate analysis. The results are
expressed as hazard ratios (HRs) with 95%CIs. Statistical
significance was set at p  0.05. Analysis was performed
using SAS (Statistical Analysis System; SAS Institute Inc.,
Cary, NC, version 9.1) software.
RESULTS
Patient Characteristics
From June 2001 to August 2008, a total of 192 Cauca-
sian patients were enrolled in this study. Patient characteris-
tics are shown in Table 2. Median age was 63 years (range,
25–81 years); 74.0% were male; 74.5% were smokers; 94.3%
had performance status 0–1; 41.7% had adenocarcinoma, and
76.0% had stage IV disease. Of the 192 patients studied, 165
patients (85.9%) received cisplatin/gemcitabine regimens, 15
(7.8%) cisplatin/taxol regimens, 9 (4.7%) cisplatin/vinorel-
bine regimens, and 3 (1.6%) received gemcitabine alone.
Genotype Information
The polymorphisms of genes ERCC1 C118T, P53
Arg72Pro, XRCC3 Thr241Met, and XPD Lys751Gln were
evaluated in 189 patients who were treated with cisplatin-
based regimens, whereas the polymorphisms of genes RRM1
C524T, CDA C435T, CDA Lys27Gln were analyzed in 168
patients who were treated with gemcitabine-based regimens.
The distribution of all these polymorphisms and the allelic
frequencies are shown in Table 3. All polymorphisms fol-
lowed Hardy-Weinberg’s equilibrium and genotype frequen-
cies for all polymorphisms were comparable with those
reported in previous studies in a Caucasian population of
NSCLC patients.12,30 XRCC3 Thr241Met was found more
frequently in smoker patients (p  0.006) and RRM1 CT
genotype in stage IV (p  0.03).
No significant correlations were detected among
ERCC1 C118T, P53 Arg72Pro, XRCC3 Thr241Met, XPD
Lys751Gln, CDA Lys27Gln, CDA C435T genotypes and age,
gender, Eastern Cooperative Oncology Group Performance
Status (ECOG-PS), histology, or clinical stage.
Correlation Between Polymorphisms and
Response to Chemotherapy
The overall best response rate was 32.3%, stable dis-
ease 25.0%, and disease progression 42.7%. A significant
TABLE 1. SNPs Evaluated
Gene Chromosome SNP
Reference SNP
ID Numbera
CDA 1p36.12b Exon 2, 79AC, K27Q 2072671
Exon 4, 435CT, T145T 1048977
RRM1 11p15.4d 5 UTR, CT, C524T 11030918
ERCC1 19q13.32a Exon 4, 33CT, N118N 11615
XRCC3 14q32.33q Exon 7, CT, T241M 861539
XPD 19q13.32a Exon 23, AC, K751Q 13181
P53 17p13.1d Exon 4, GC, R72P 1042522
a Available at http://www.ncbi.nih.gov/projects/SNP/.
UTR, untranslated region.
TABLE 2. Clinical and Demographic Characteristics of
NSCLC Patients
Characteristics No. of Patients (%)
All 192 (100)
Median age (yr) 63 (range, 25–81)
Gender
Male 142 (74.0)
Female 50 (26.0)
Smoking history
Never smokers 24 (12.5)
Former/current smokers 143 (74.5)
Unknown 25 (13.0)
ECOG-PS
0–1 181 (94.3)
2 11 (5.7)
Histology
ADC 80 (41.7)
SQC 52 (27.1)
Other 60 (31.2)
Stage
IIIB 46 (24.0)
IV 146 (76.0)
ECOG-PS, Eastern Cooperative Oncology Group Performance Status; ADC, ade-
nocarcinoma; SQC, squamous carcinoma.
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correlation was shown between better response to cisplatin/
gemcitabine-based chemotherapy and CDA C435T genotype:
54.6% of the patients carrying the CDA T/T genotype expe-
rienced partial response, whereas only 28.8% of CDA C/T
and 27.5% of CDA C/C patients responded to therapy (p 
0.03; Table 4). In the multivariate logistic regression model
including performance status, age, and type of treatment
regimen, the CDA 435 T/T genotype remained significantly
associated with a better response to cisplatin/gemcitabine-
based chemotherapy (p  0.04, Table 4). No significant
correlations were observed between ERCC1 C118T, P53
Arg72Pro, XRCC3 Thr241Met, XPD Lys751Gln, CDA
Lys27Gln, and RRM1 C524T genotypes and objective re-
sponse.
Toxicity Analysis
As outlined in Table 5, a significant difference in severe
nonhematologic toxicity was observed according to CDA
C435T genotype, with grade 3 in 14.3% of heterozygous
patients for the CDA C/T, in contrast to 2.8% of those who
were C/C homozygous (p  0.03). No other significant
differences in toxicity were found with respect to the other
polymorphisms. In the multivariate logistic regression model
including performance status, age, and type of treatment
regimen, the CDA 435 C/T genotype was associated with a
significantly increased risk of nonhematologic toxicity of
grade 3 (p  0.02, Table 5).
Survival Analysis
At a median follow-up of 24.6 months (25th-75th
percentile, 14.5–40.8 months), 66.7% (128/192) of patients
died. The median OS and PFS time were 12.7 and 4.7
months, respectively. At univariate analysis, age 63 years
(median value) and ECOG-PS 0 were statistically signifi-
cantly associated with longer PFS (p  0.022 and p  0.002,
respectively, Table 6). The univariate analysis of OS showed
that age 63 years (HR  0.71; 95% CI  0.50–0.99; p 
0.049), ECOG-PS 0 (HR  0.49; 95% CI  0.34–0.69; p 
0.0001), never-smoker (HR  0.45; 95% CI  0.24–0.85;
p  0.014), and adenocarcinoma histology (HR  0.52; 95%
CI  0.36–0.75; p  0.0005) were statistically significantly
associated with longer OS (Table 6). No significant differ-
ences in PFS and OS were observed with respect to ERCC1
C118T, P53 Arg72Pro, XRCC3 Thr241Met, CDA Lys27Gln,
CDA C435T, and RRM1 C524T genotypes. A multivariate
Cox regression model for PFS showed that the XPD 751 CC
genotype (HR  0.58; 95% CI  0.39–0.85; p  0.006,
Figure 1), ECOG-PS 0 (HR  0.58; 95% CI  0.42–0.79;
p  0.0006), and age 63 years (HR  0.61; 95% CI 
0.45–0.84; p  0.002) were significantly associated with
longer PFS. A multivariate Cox regression model for OS
showed that age 63 years (HR  0.59; 95% CI  0.41–
0.86; p  0.007), ECOG-PS 0 (HR  0.49; 95% CI 
0.33–0.73; p  0.0005), never-smoker (HR  0.45; 95%
CI  0.24–0.85; p  0.014), and adenocarcinoma histology
(HR  0.57; 95% CI  0.38–0.86; p  0.008) were the
independent prognostic factors for OS (Table 6).
DISCUSSION
In this study, we evaluated polymorphisms of key
genes involved in the mechanism of action or metabolism of
cisplatin and gemcitabine. CDA, an enzyme involved in the
pyrimidines salvage pathway, is the major gemcitabine inac-
tivation enzyme. Therefore, patients with impaired CDA
activity might develop strong toxicities after administration
of gemcitabine, while CDA overexpression in tumor tissues
might reduce the antitumor efficacy of this drug. An in vitro
study has demonstrated resistance to gemcitabine in cells
overexpressing CDA.31 Three main SNPs were identified in
the CDA gene: CDA 435 CT not encoded for an amino acid
change, CDA 79 AC encoded for a lysine to glutamine
amino acid change (K27Q), and CDA 208GA encoded for
an alanine to threonine amino acid change (A70T).23 In
Asians, the 208 GA polymorphism is associated with al-
teration of gemcitabine pharmacokinetics and subsequent
severe hematologic toxicities.27,28 Another pivotal clinical
study, in Caucasians, has demonstrated that the 79 AC
polymorphism could have an impact on CDA activity and
clinical outcome in patients treated with gemcitabine plus
cisplatin, thus suggesting that screening for this mutation
could be a predictive marker at the bedside.30
In this study, we evaluated two SNPs, the CDA 435
CT and CDA 79 AC (Lys27Gln) identified in the CDA
gene; the genotype frequencies for these polymorphisms were
TABLE 3. Genotypic and Allelic Frequencies
Genotype
No. of
Patients (%) Allelic Frequencies
CDA (C435T) C 0.67; T 0.33
CC 80 (47.6)
CT 66 (39.3)
TT 22 (13.1)
CDA (Lys27Gln) A(Lys) 0.59; C(Gln) 0.41
AA 54 (32.1)
AC 91 (54.2)
CC 23 (13.7)
RRM1 (C524T) T 0.69; C 0.31
TT 77 (45.9)
CT 78 (46.4)
CC 13 (7.7)
ERCC1 (C118T) C 0.56; T 0.44
CC 54 (28.6)
CT 104 (55.0)
TT 31 (16.4)
XRCC3 (Thr241Met) T (Thr) 0.47; C (Met) 0.53
TT 46 (24.3)
CT 85 (45.0)
CC 58 (30.7)
XPD (Lys751Gln) A(Lys) 0.54; C (Gln) 0.46
AA 57 (30.1)
AC 91 (48.2)
CC 41 (21.7)
P53 (Arg72Pro) G(Arg) 0.73; C (Pro) 0.27
GG 97 (51.3)
GC 81 (42.9)
CC 11 (5.8)
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comparable with those reported in previous studies in a
Caucasian population of NSCLC patients.21 Nevertheless, the
CDA G208A was not detected in Caucasians32 and for this
reason, it is not evaluated in our study. Our data show that the
CDA C435T variant T allele was associated with a better
response, suggesting reduced enzyme activity conferred by
this allele resulted in a higher level of drug availability. Based
on the results of the analyses of the 345 CT SNP, we
observed that decreased CDA activity might have been re-
sponsible for the severe drug toxicity found in this data
setting. A significant difference in severe nonhematologic
toxicity was observed according to CDA genotype, with
grades 3–4 in 14.3% of heterozygous patients for the CDA
345 CT, in contrast to 2.8% of those who were CC homozy-
gous (p  0.03), and this effect was also maintained in the
multivariate model (p 0.02) after adjusting for performance
status, age, and type of treatment regimen. Our result was
specific to gastrointestinal toxicity. Esophagitis reflects a
direct damage on the mucosal tissues of the gastrointestinal
tract. Chemotherapy-induced nausea/vomiting is thought to
be mediated by a complex interplay between the gastrointes-
tinal tract and the central and peripheral nervous systems.
Although the exact mechanism has yet to be determined,
tissue damage to the normal gastrointestinal tissue is thought
to be a contributing factor.
No other significant differences in toxicity were found
with respect to the other polymorphisms. Nevertheless, CDA
C435T polymorphism was not associated with survival. The
multivariate analysis of PFS showed that the polymorphism
of XPD 751 C/C variant, which is essential for transcription
during nucleotide excision repair, was associated with longer
PFS. Matullo et al14 found that a polymorphism in codon 751
(Lys to Gln) of XPD was associated with differences in the
levels of bulky DNA adducts. Among XPD 751 GlnGln
carriers, extremely low levels of DNA adducts were detected
in smokers, whereas nonsmokers had high levels. Experimen-
tal evidence indicates that XPD overexpression leads to
cisplatin resistance.33 In contrast, it has also been reported
that XPD variant alleles (Gln751 or Asn312) were associ-
ated with reduced DNA repair capacity as measured by
host cell reactivation assay.34 Nevertheless, gene-smoking
interaction for these XPD polymorphisms has been docu-
mented; Gln751 and Asn312 variants were risk factors of
lung cancer in nonsmokers but protective factors in heavy
TABLE 4. Response to Chemotherapy According to All Genotypes
Genotype PR, n. (%) SD  PD, n (%)
Univariate Model
OR (95% CI) pa
Multivariate Modelb
OR (95% CI) pa
CDA (C435T)
CC 22 (27.5) 58 (72.5) 1.0 (Reference) 1.0 (Reference)
CT 19 (28.8) 47 (71.2) 0.95 (0.48–1.87) 0.88 0.83 (0.41–1.67) 0.60
TT 12 (54.6) 10 (45.4) 2.82 (1.10–7.22) 0.03 2.67 (1.03–6.88) 0.04
CDA (Lys27Gln)
AA 18 (33.3) 36 (66.7) 1.0 (Reference) 1.0 (Reference)
AC 25 (27.5) 66 (72.5) 0.72 (0.37–1.38) 0.32 0.70 (0.36–1.36) 0.29
CC 10 (43.5) 13 (56.5) 1.45 (0.56–3.75) 0.43 1.37 (0.52–3.60) 0.52
RRM1 (C524T)
CC 3 (23.1) 10 (76.9) 1.0 (Reference) 1.0 (Reference)
CT 26 (33.3) 52 (66.7) 1.04 (0.45–2.40) 0.92 1.01 (0.44–2.36) 0.97
TT 24 (31.2) 53 (68.8) 0.94 (0.40–2.19) 0.89 0.87 (0.37–2.04) 0.74
ERCC1 (C118T)
CC 16 (29.6) 38 (70.4) 1.0 (Reference) 1.0 (Reference)
CT 36 (34.6) 68 (65.4) 1.35 (0.67–2.74) 0.39 1.31 (0.64–2.71) 0.46
TT 10 (32.3) 21 (67.7) 1.22 (0.47–3.15) 0.68 1.18 (0.45–3.09) 0.73
XRCC3 (Thr241Met)
TT 19 (41.3) 27 (58.7) 1.0 (Reference) 1.0 (Reference)
CT 28 (33.0) 57 (67.0) 0.77 (0.37–1.61) 0.49 0.70 (0.33–1.47) 0.34
CC 15 (25.9) 43 (74.1) 0.55 (0.24–1.25) 0.15 0.50 (0.21–1.15) 0.10
XPD (Lys751Gln)
AA 17 (29.8) 40 (70.2) 1.0 (Reference) 1.0 (Reference)
AC 29 (31.9) 62 (68.1) 1.18 (0.57–2.41) 0.64 1.13 (0.55–2.34) 0.74
CC 16 (39.0) 25 (61.0) 1.61 (0.69–3.75) 0.26 1.55 (0.66–3.63) 0.31
P53 (Arg72Pro)
GG 35 (36.1) 62 (63.9) 1.0 (Reference) 1.0 (Reference)
GC 23 (28.4) 58 (71.6) 0.73 (0.39–1.38) 0.34 0.70 (0.37–1.33) 0.28
CC 4 (36.4) 7 (63.6) 1.06 (0.29–3.87) 0.92 1.04 (0.28–3.82) 0.96
a p  0.05 statistically significant.
b Age, performance status, and type of treatment regimen were included in the model together with each genotype.
PR, partial response; SD, stable disease; PD, progressive disease; OR, odds ratio.
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smokers, when compared with the Lys751 and Asp312
homozygous wild types.35
In our study, the patients with XPD 751 C/C variant
were heavy smokers conferring a better clinical outcome. The
exact mechanism of how cigarette smoking changes the DNA
repair capacity (DRC) posed by each genotype of these DNA
repair genetic polymorphisms is unknown. One possible
explanation may be that different DRCs of different geno-
types are overwhelmed by heavy smoking exposure. Alter-
nately, cigarette smoking may stimulate DRC in response to
the DNA damage caused by tobacco carcinogens, because
heavy smokers among both lung cancer patients and controls
may have more proficient DRC in lymphocytes than non- or
light smokers, and DNA repair gene expression was in-
creased in heavy smokers.35 No other polymorphism in any of
the genes included in this study was significantly related to
survival, and these data are in agreement with those of a
recent study carried out by De las Pen˜as et al12 in advanced
NSCLC patients treated with cisplatin plus gemcitabine.
Interestingly, in this study, patients harboring XRCC3
Met241Met genotype lived longer than patients with other
XRCC3 241 polymorphisms, even if no correlation with
response has been reported. Previous studies on ERCC1 and
XPD SNPs and their predictive role of clinical outcome
reported controversial results; furthermore, most of these
trials were carried out in patients treated with different
platinum-based regimens,7,8,11,36,37 not allowing definitive
conclusions. Multiple reasons may explain the different re-
sults obtained in the association between some SNPs and
survival. Most published studies are in different tumor types,
with a variety of treatment regimens and population differ-
ences. In our study, focusing only on scientifically sensitive
comparisons, a policy of not making adjustments for multiple
comparisons is taken to avoid missing important findings.
Nevertheless, this study has a number of limitations.
First, the effects of the SNP on the enzymatic or
nonenzymatic functions of the CDA 435CT protein is not
exactly known. Second, these findings should be validated in
a prospective study with a larger group of patients and a more
comprehensive series of polymorphisms. Third, it is quite
TABLE 5. Grade 3 to 4 Toxicity According to All Genotypes
Genotype
Hematologic Toxicity Nonhematologic Toxicity
n (%)
Univariate Model Multivariate Modela
n (%)
Univariate Model Multivariate Modela
OR (95% CI) pb OR (95% CI) pb OR (95% CI) pb OR (95% CI) pb
CDA (C435T)
CC 15 (20.8) 1 (Reference) 1 (Reference) 2 (2.8) 1 (Reference) 1 (Reference)
CT 10 (15.9) 0.65 (0.28–1.53) 0.32 0.62 (0.26–1.46) 0.27 9 (14.3) 4.55 (1.18–17.5) 0.03 5.64 (1.34–23.75) 0.02
TT 2 (9.5) 0.36 (0.07–1.71) 0.20 0.35 (0.08–1.66) 0.19 3 (14.3) 4.55 (0.84–24.4) 0.08 5.01 (0.88–28.59) 0.07
CDA (Lys27Gln)
AA 9 (17.7) 1 (Reference) 1 (Reference) 4 (7.8) 1 (Reference) 1 (Reference)
AC 16 (19.1) 0.92 (0.41–2.09) 0.85 0.97 (0.43–2.22) 0.95 7 (8.3) 1.07 (0.32–3.55) 0.91 1.29 (0.38–4.42) 0.68
CC 2 (9.5) 0.41 (0.09–2.00) 0.27 0.42 (0.09–2.05) 0.28 3 (14.3) 1.97 (0.43–9.04) 0.38 2.52 (0.52–12.31) 0.25
RRM1 (C524T)
CC 2 (15.4) 1 (Reference) 1 (Reference) 3 (23.1) 1 (Reference) 1 (Reference)
CT 14 (19.4) 0.80 (0.27–2.38) 0.69 0.83 (0.28–2.45) 0.73 7 (9.7) 0.59 (0.16–2.22) 0.44 0.62 (0.16–2.35) 0.48
TT 11 (15.5) 0.61 (0.20–1.86) 0.39 0.62 (0.20–1.90) 0.40 4 (5.6) 0.33 (0.08–1.42) 0.14 0.36 (0.08–1.57) 0.17
ERCC1 (C118T)
CC 8 (16.7) 1 (Reference) 1 (Reference) 2 (4.2) 1 (Reference) 1 (Reference)
CT 15 (16.0) 1.02 (0.40–2.60) 0.96 0.92 (0.35–2.39) 0.86 11 (11.7) 3.20 (0.69–15.2) 0.13 2.75 (0.57–13.34) 0.21
TT 8 (33.3) 2.68 (0.86–8.36) 0.08 2.47 (0.79–7.72) 0.12 2 (8.3) 2.20 (0.29–16.8) 0.43 2.04 (0.27–15.54) 0.46
XRCC3 (Thr241Met)
TT 9 (20.5) 1 (Reference) 1 (Reference) 7 (15.9) 1 (Reference) 1 (Reference)
CT 13 (18.3) 0.95 (0.37–2.43) 0.91 0.88 (0.34–2.27) 0.80 6 (8.5) 0.53 (0.17–1.68) 0.28 0.51 (0.16–1.65) 0.26
CC 9 (17.7) 0.90 (0.32–2.52) 0.85 0.85 (0.30–2.38) 0.87 2 (3.9) 0.23 (0.05–1.19) 0.08 0.22 (0.04–1.14) 0.07
XPD (Lys751Gln)
AA 9 (18.0) 1 (Reference) 1 (Reference) 6 (12.0) 1 (Reference) 1 (Reference)
AC 16 (20.0) 1.22 (0.49–3.01) 0.66 1.12 (0.45–2.81) 0.80 5 (6.3) 0.52 (0.15–1.81) 0.31 0.43 (0.12–1.56) 0.20
CC 6 (16.7) 0.98 (0.31–3.03) 0.97 0.91 (0.29–2.84) 0.87 4 (11.1) 0.98 (0.26–3.75) 0.98 0.93 (0.24–3.59) 0.91
P53 (Arg72Pro)
GG 17 (19.1) 1 (Reference) 1 (Reference) 7 (7.9) 1 (Reference) 1 (Reference)
GC 14 (20.6) 1.14 (0.52–2.52) 0.74 1.10 (0.50–2.42) 0.82 6 (8.8) 1.18 (0.38–3.67) 0.78 1.17 (0.37–3.70) 0.79
CC 0 — — — — 2 (22.2) 3.47 (0.60–19.97) 0.16 3.50 (0.59–20.62) 0.16
a Age, performance status and type of treatment regimen were included in the model together with each genotype.
b p  0.05 statistically significant.
OR, odds ratio.
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unlikely that the effect of a single common sequence variant
on outcomes will be easily detectable in a population-based
study such as the present one, whereas a combination of
multiple sequence variants functioning in the same biochem-
ical pathway might be more important in the identification of
different risks for survival and other clinically relevant effi-
cacy outcomes. Fourth, the retrospective nature of this study
and the possibility for ascertainment bias, particularly with
regard to toxicity outcomes. Although multiple sources of
documentation were searched to find as much toxicity infor-
mation as possible, documentation of toxicity is at the dis-
cretion of the treating clinicians, and this can vary by physi-
cian, by type of regimen being used, and by treatment on or
off protocol. Grading of toxicity can also be subjective,
although the widespread acceptance and use of the National
Cancer Institute Common Toxicity Criteria within the medi-
cal oncology group has in large part standardized toxicity
grading among clinicians. Of note, although there may have
been variable recording and grading of toxicity outcomes, it
is very unlikely that there would have been a systematic
difference based on polymorphism status, which was un-
known to the physicians at the time of treatment. Neverthe-
less, prospective studies will be needed to eliminate many of
these potential biases and to validate the hypotheses gener-
ated from this study.
Furthermore, our analysis includes a highly homoge-
neous cohort of advanced NSCLC patients who may have
contributed to highlight the relevance of these variants in the
response, toxicity, and PFS of patients treated with cisplatin/
gemcitabine-based regimen.
In conclusion, to our knowledge, this is the first in vivo
study to analyze the predictive role of CDA 435CT poly-
morphism. We reported a correlation of this polymorphism
with response and toxicity in NSCLC patients treated with
cisplatin/gemcitabine-based therapy. We believe that the
analysis of CDA genotype should be incorporated into future
prospective trials with gemcitabine, alone or in combination,
to identify the best marker to secure the administration of this
widely prescribed anticancer therapy.
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